KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Depreciation and Depletion: 2016-2024

Historic Depreciation and Depletion for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to $62.6 million.

  • Amneal Pharmaceuticals' Depreciation and Depletion rose 56.19% to $18.6 million in Q4 2018 from the same period last year, while for Dec 2018 it was $60.9 million, marking a year-over-year change of. This contributed to the annual value of $62.6 million for FY2024, which is 5.44% down from last year.
  • As of FY2024, Amneal Pharmaceuticals' Depreciation and Depletion stood at $62.6 million, which was down 5.44% from $66.2 million recorded in FY2023.
  • Amneal Pharmaceuticals' Depreciation and Depletion's 5-year high stood at $68.1 million during FY2022, with a 5-year trough of $60.4 million in FY2020.
  • For the 3-year period, Amneal Pharmaceuticals' Depreciation and Depletion averaged around $65.6 million, with its median value being $66.2 million (2023).
  • In the last 5 years, Amneal Pharmaceuticals' Depreciation and Depletion rose by 12.19% in 2022 and then declined by 5.44% in 2024.
  • Yearly analysis of 5 years shows Amneal Pharmaceuticals' Depreciation and Depletion stood at $60.4 million in 2020, then climbed by 0.46% to $60.7 million in 2021, then climbed by 12.19% to $68.1 million in 2022, then dropped by 2.79% to $66.2 million in 2023, then fell by 5.44% to $62.6 million in 2024.